An Open-label, Multi-centre Study to Evaluate Efficacy and Safety of Gefitinib as the First-line Treatment for Locally Advanced (IIIB), Metastatic (IV) or Recurrent Pulmonary Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation.
收藏DataCite Commons2024-12-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00006144/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to evaluate the overall objective tumor response rate (ORR) of Gefitinib.
提供机构：
Vivli
创建时间：
2020-10-30
